VCYT
Price:
$41.17
Market Cap:
$3.19B
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to hel...[Read more]
Industry
Biotechnology
IPO Date
2013-10-30
Stock Exchange
NASDAQ
Ticker
VCYT
According to Veracyte, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -316.69. This represents a change of 952.77% compared to the average of -30.08 of the last 4 quarters.
The mean historical PE Ratio of Veracyte, Inc. over the last ten years is -30.83. The current -316.69 PE Ratio has changed 102.61% with respect to the historical average. Over the past ten years (40 quarters), VCYT's PE Ratio was at its highest in in the June 2024 quarter at 71.18. The PE Ratio was at its lowest in in the September 2019 quarter at -399.36.
Average
-30.83
Median
-23.55
Minimum
-78.16
Maximum
-5.54
Discovering the peaks and valleys of Veracyte, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 285.99%
Maximum Annual PE Ratio = -5.54
Minimum Annual Increase = -49.07%
Minimum Annual PE Ratio = -78.16
Year | PE Ratio | Change |
---|---|---|
2023 | -26.86 | -42.16% |
2022 | -46.44 | 25.46% |
2021 | -37.02 | -49.07% |
2020 | -72.68 | -7.01% |
2019 | -78.16 | 285.99% |
2018 | -20.25 | 183.38% |
2017 | -7.15 | 0.41% |
2016 | -7.12 | 28.40% |
2015 | -5.54 | -22.12% |
2014 | -7.12 | 201.89% |
The current PE Ratio of Veracyte, Inc. (VCYT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-36.77
5-year avg
-52.23
10-year avg
-30.83
Veracyte, Inc.’s PE Ratio is less than Crinetics Pharmaceuticals, Inc. (-15.40), less than Viridian Therapeutics, Inc. (-4.95), less than Cytokinetics, Incorporated (-9.85), less than Structure Therapeutics Inc. (-12.71), less than Icosavax, Inc. (-15.78), less than Kura Oncology, Inc. (-3.90), less than Protagonist Therapeutics, Inc. (14.12), less than Merus N.V. (-11.84), less than Replimune Group, Inc. (-4.61), less than Cerevel Therapeutics Holdings, Inc. (-17.73), less than Enanta Pharmaceuticals, Inc. (-1.11), less than Syndax Pharmaceuticals, Inc. (-3.74), less than Ventyx Biosciences, Inc. (-1.05), less than uniQure N.V. (-3.52), less than Rocket Pharmaceuticals, Inc. (-4.29), less than Rhythm Pharmaceuticals, Inc. (-13.04), less than Solid Biosciences Inc. (-1.68), less than MeiraGTx Holdings plc (-5.00), less than IDEAYA Biosciences, Inc. (-12.32), less than AnaptysBio, Inc. (-2.44), less than Keros Therapeutics, Inc. (-3.33), less than Homology Medicines, Inc. (-0.01),
Company | PE Ratio | Market cap |
---|---|---|
-15.40 | $4.95B | |
-4.95 | $1.52B | |
-9.85 | $5.69B | |
-12.71 | $1.63B | |
-15.78 | $769.04M | |
-3.90 | $688.99M | |
14.12 | $2.33B | |
-11.84 | $2.90B | |
-4.61 | $941.76M | |
-17.73 | $8.19B | |
-1.11 | $129.50M | |
-3.74 | $1.11B | |
-1.05 | $160.16M | |
-3.52 | $842.77M | |
-4.29 | $1.25B | |
-13.04 | $3.41B | |
-1.68 | $165.81M | |
-5.00 | $480.64M | |
-12.32 | $2.20B | |
-2.44 | $426.00M | |
-3.33 | $679.31M | |
-0.01 | $3.02M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Veracyte, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Veracyte, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Veracyte, Inc.'s PE Ratio?
How is the PE Ratio calculated for Veracyte, Inc. (VCYT)?
What is the highest PE Ratio for Veracyte, Inc. (VCYT)?
What is the 3-year average PE Ratio for Veracyte, Inc. (VCYT)?
What is the 5-year average PE Ratio for Veracyte, Inc. (VCYT)?
How does the current PE Ratio for Veracyte, Inc. (VCYT) compare to its historical average?